ERBB2 and neoplasm: Chaganty et al. (8) previously reported that targeting HER2 with trastuzumab could upregulate PD-L1 expression in tumor cells by inducing IFN-γ production in the tumor microenvironment, thereby contributing to induced immune resistance to HER2 targeted therapy.